Scribe Therapeutics surges 67% after $129M IPO as biotech market heats up

Scribe Therapeutics raised $128.7 million in gross proceeds and watched its stock climb roughly 67% on its first day of trading on the Nasdaq. The company sold 8.58 million shares at $15 each, the top end of its price range, under the ticker SCTX.

What Scribe actually does

Scribe Therapeutics was founded between 2017 and 2018, emerging from UC Berkeley’s Doudna Lab. Rather than making permanent cuts to DNA, Scribe’s approach focuses on epigenetic silencing — their technology tells certain genes to be quiet without permanently altering the underlying DNA.

Their lead candidate, STX-1150, is currently in Phase 1 clinical trials targeting LDL cholesterol reduction. The company also has a preclinical program called STX-1200, which aims to reduce levels of lipoprotein(a), or Lp(a). Preclinical data showed STX-1200 achieved over 90% knockdown of Lp(a) in models.

The money trail and big pharma validation

The company’s initial funding included $20 million from Andreessen Horowitz. By March 2026, the company’s cash position sat at approximately $50 million. Scribe has established partnerships with Biogen, Sanofi, and Eli Lilly. The collaboration agreements with these partners provide milestone payments and potential royalties, generating revenue before any Scribe product reaches the market.

Scribe originally planned a smaller offering but expanded it to meet demand, ultimately landing at 8.58 million shares at $15 each.

Scribe is still a clinical-stage company. STX-1150 is only in Phase 1 trials, meaning years of additional testing, regulatory review, and potential setbacks stand between today’s share price and actual revenue generation. Investors buying at post-IPO levels are paying a meaningful premium over those who got in at $15.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.